ICU Medical, Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual report, not a standalone fourth-quarter report. ICU Medical develops and sells infusion systems and consumables, IV solutions, vascular access and critical-care products.
Financial performance
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $2.280 billion | $1.316 billion |
| Gross profit / margin | $697.8 million / 30.6% | $491.5 million / 37.3% |
| Operating income (loss) | $(42.9) million | $123.2 million |
| Net income (loss) | $(74.3) million; $(3.11) diluted EPS | $103.1 million; $4.74 diluted EPS |
| Operating cash flow | $(62.1) million | $267.5 million |
| Capital expenditures | $90.3 million | $68.5 million |
Revenue rose about 73%, mainly because Smiths Medical was acquired on January 6, 2022 and contributed approximately $950.7 million of revenue from January 7 through year-end. Legacy Infusion Consumables revenue grew 2.1%; Infusion Systems declined 0.3%; IV Solutions grew 1.1%; and Critical Care declined 4.1%. Smiths Medical product lines generated $340.1 million in Infusion Systems, $326.8 million in Vascular Access and $284.6 million in Vital Care revenue.
Gross margin fell to 30.6%, reflecting Smiths Medical’s lower margins, purchase-accounting inventory step-up, quality-system and product remediation spending, inflation in materials, labor and freight, and lower manufacturing absorption amid supply constraints. SG&A rose to $608.3 million from $302.6 million, and R&D to $93.0 million from $47.5 million, principally due to the acquisition. Restructuring, strategic transaction and integration expenses were $71.4 million. Interest expense was $70.8 million, compared with $0.9 million in 2021. A $40.1 million income-tax benefit partly offset the pretax loss.
Liquidity, debt and cash flow
Year-end cash, cash equivalents and short-term investments totaled $213.0 million, down from $567.2 million. Current assets were $1.235 billion and current liabilities $494.6 million. Long-term debt had a $1.678 billion principal balance ($1.653 billion carrying value before current portion presentation); no revolver borrowings were outstanding. The $500 million revolving facility remains available, subject to its terms. The company reported compliance with its debt covenants at year-end and said existing cash, expected operating cash flow and available borrowing capacity should fund requirements for the next 12 months.
Operating cash flow turned negative, principally because inventory increased $201.1 million as the company built safety stock, alongside higher tax-related cash use and reductions in accrued liabilities. Investing cash use was $1.909 billion, largely reflecting the Smiths Medical acquisition; financing activities provided $1.637 billion, primarily from new debt. Management estimates 2023 capital expenditures of $100–$120 million and 2023 restructuring, integration and quality-compliance investment of $75–$125 million. These are estimates, not earnings guidance.
Material developments, outlook and risks
- Smiths Medical acquisition: Consideration was $2.552 billion, including $1.923 billion cash, 2.5 million ICU Medical shares and contingent consideration. Integration, customer retention, operational recovery and realization of anticipated benefits remain important execution risks.
- Operating conditions: Management cited inflation, higher freight and labor costs, supply constraints, foreign-exchange effects, and COVID-19-related changes in hospital admissions and procedures. Smiths Medical product revenues were affected by lower demand and supply-chain and fulfillment challenges.
- Regulatory and remediation exposure: Smiths Medical had received an FDA Warning Letter following an Oakdale, Minnesota facility inspection. The year-end estimated field-service corrective-action liability was $49.8 million; actual costs may differ. The filing also discusses a 2020 Class I Medfusion syringe-pump recall and uncertainty about completion and costs.
- Debt and rates: Borrowings are variable-rate, partly hedged with interest-rate swaps. The filing estimates a 1% SOFR change would affect annual interest expense by approximately $16.8 million before considering the swaps’ effects. Debt covenants and leverage may constrain financial flexibility.
- Concentration and other risks: Medline accounted for 15% of 2022 consolidated sales. ICU Medical also identifies reliance on single- or limited-source suppliers, pricing pressure, competition, foreign-exchange exposure, cybersecurity, regulatory compliance and integration risks.
- Contingencies and controls: Management said routine unsettled legal proceedings were not expected to materially affect financial position or results. The financial-statement audit opinion was unqualified. Management and the auditor reported effective internal control overall, but Smiths Medical—about 40% of assets and 42% of revenue—was excluded from the internal-control assessment.
- Outlook: The filing provides no specific revenue, earnings or margin guidance. Management said the effects of macroeconomic conditions, COVID-19 and the Ukraine conflict remain uncertain. The company has not historically paid dividends and does not anticipate doing so in the foreseeable future.
Important facts for investors to verify
- Whether acquired Smiths Medical operations recover from supply, fulfillment and demand challenges and achieve expected integration benefits.
- Whether gross margins and operating cash flow improve as inflation, inventory levels and acquisition-related costs evolve.
- Progress and actual spending on the $49.8 million field-service corrective action, FDA Warning Letter remediation and other quality initiatives.
- Debt reduction, interest-rate exposure, covenant headroom and liquidity against scheduled principal and interest payments.
- Customer concentration, especially Medline, and the company’s ability to maintain supply, customer relationships and pricing.